Schrodinger (SDGR) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Schrodinger (SDGR) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 39.2% versus a loss of 33.4%. Schrodinger is the larger company by market cap ($1.72 billion vs $1.62 billion), about 1.1 times the size, while Zenas BioPharma is growing revenue faster (+100.0% vs +23.3%). Schrodinger converts more of its revenue into profit, with a net margin of -40.4% versus -3777.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDGR | ZBIO |
|---|---|---|
| Share price | $22.93 | $23.85 |
| Market cap | $1.72B | $1.62B |
| 1-day change | -12.95% | -4.75% |
| YTD return | +28.24% | -34.32% |
| 1-year return | +39.22% | -33.38% |
| 5-year return | -42.01% | — |
| EPS (TTM) | $-0.79 | $-9.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $255.87M | $10.00M |
| Revenue growth (YoY) | +23.29% | +100.00% |
| Net income (latest FY) | $-103.27M | $-377.74M |
| Gross margin | 55.74% | — |
| Operating margin | -65.23% | -3830.57% |
| Net margin | -40.36% | -3777.37% |
| 52-week high | $34.00 | $44.60 |
| 52-week low | $10.95 | $13.50 |
| Distance from 52-week high | -32.56% | -46.52% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +46.40% | +100.75% |
| Average volume | 2.08M | 593.08K |
| Shares outstanding | 65.91M | 67.82M |
| Employees | 850 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDGR has outperformed ZBIO by 72.6 percentage points over the past year.
- Schrodinger is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
- Zenas BioPharma grew revenue faster in its latest fiscal year (+100.00% vs +23.29%).
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
SDGR vs ZBIO FAQ
Which is bigger, Schrodinger or Zenas BioPharma?
Schrodinger (SDGR) is larger, with a market capitalization of $1.72B compared with $1.62B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, SDGR or ZBIO?
SDGR returned +39.22% over the past 12 months, compared with -33.38% for ZBIO (price return, excluding dividends). Past performance does not predict future results.
Are Schrodinger and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.